Duchenne muscular dystrophy (DMD) is one of the most common genetic diseases in humans with an incidence of 1 in 3,500 male births. Duchenne and other muscular dystrophies are characterized by progressive muscle weakness and wasting. In the 1980s, dystrophin was identified as the gene defective in DMD. It is now known that dystrophin is a component of the dystrophin-glycoprotein complex (DGC), which is found in the plasma membrane of muscle cells (including neuromuscular junctions). Genetic defects in components of the DGC result in many different forms of muscular dystrophy. The DGC links the cytoskeleton to the extracellular matrix and is thought to be important for maintaining muscle structural stability and organizing signaling molecules. The exact role of the DGC in the pathogenesis of disease has, however, remained uncertain. C. elegans possesses most of the DGC components found in mammals, albeit with less diversity. Segalat and colleagues have shown that mutations in C. elegans DGC genes (such as
dys-1 , a dystrophin homologue) lead to an exaggerated bending of the anterior body and head during forward movement, hypersensitivity to aldicarb and acetylcholine, and muscle degeneration in a sensitized (
hlh-1 ) genetic background. Previously, we identified twelve mutants with phenotypes that are indistinguishable from those of the DGC mutants, including five alleles (
eg28 ,
eg114 ,
eg115 ,
eg121 ,
eg137 ) of a novel gene. We cloned the novel gene based on the locomotory phenotype. The gene encodes
snf-6 , a member of the sodium-dependent neurotransmitter transporter family. Tissue-specific rescue experiments indicate that
snf-6 functions in muscle cells. In an in vitro uptake assay using radio-labeled substrates we found that SNF-6 transports acetylcholine and choline in a saturable and sodium-dependent manner. Consistent with these results, GFP-tagged SNF-6 expressed under the control of a muscle-specific
myo-3 promoter was observed in the end of muscle arms where neuromuscular junctions are located. Whole-cell voltage-clamped current recordings from body wall muscles suggest that SNF-6 clears acetylcholine at neuromuscular junctions. Evoked responses after a single stimulation are the same in
snf-6 and wild-type animals; however, evoked responses after repetitive stimulation are significantly greater in
snf-6 than in wild-type animals. These results are consistent with a role for SNF-6 mediated acetylcholine uptake during periods of increased synaptic activity. Several lines of evidence indicate that SNF-6 interacts with the DGC. First, co-immunoprecipitation experiments demonstrate that SNF-6 interacts in vitro with the DGC through the PDZ domain of STN-1, a b 1-syntrophin homologue. The PDZ interacting sequence in SNF-6 is required for complete rescue of the
snf-6 phenotype. Second, mutations in DGC genes cause a progressive loss of SNF-6 at neuromuscular junctions. Third, an equivalent degree of muscle degeneration occurs in
snf-6 and DGC mutants (in the same
hlh-1 background). Our studies in C. elegans suggest that improper clearing of acetylcholine and prolonged excitation of muscles may have a role in the pathogenesis of muscular dystrophies.